BTG News
6 articles
BTG's vision: The State of Israel is a world leader in biological GMP production
With 40 years of experience in the field of drug development and production, a general biotechnology company - Ferring Pharmaceuticals helps start-up companies in the field of biotech to reach the stage of clinical trials - without leaving the borders of the country
Ferring-BTG, a subsidiary of Swiss pharmaceutical company Ferring Pharmaceuticals, is helping young Israeli biotech companies transition from research to clinical trials. The company has been investing heavily in the microbiome and genetic editing fields, and is also supporting smaller companies born in academia and hospitals. Ferring-BTG has been involved in the fight against COVID-19, supporting startups in bringing vaccines and drugs against the virus to clinical trials. The company is now exploring additional partnerships, not necessarily related to vaccines/drugs for COVID-19.
PartnersExpand
https://www.jpost.com/Jpost-Tech/Biotechnology-General-opens-production-line-to-boost-manufacturing-capacity-603348
Biotechnology General (BTG), an Israeli-based company, has launched a production line that increases the capacity of mammalian drug production. The investment for the production line was $17 million. Ferring Pharmaceuticals, BTGs parent company, provided the investment. The inauguration of the production line was attended by Ferring President Per Falk, who highlighted the importance of BTG in Ferrings goal to be a world leader in reproductive medicine and maternal health. BTG is the oldest biological pharmaceutical company in Israel and has expanded over the years to become significant in the production of genetically engineered drugs. The new production line strengthens BTGs capacity for future growth and development.
InvestmentPartners
Biotech firm in Israel makes fertility waves with genetically modified hormone
Israeli biotech firm BTG has developed a new-generation fertility treatment called Rekovelle, which is a personalized hormone therapy that boosts the chances of patients seeking to get pregnant. The medication was launched by Swiss multinational pharmaceutical company Ferring, which acquired BTG in 2005. BTG genetically engineers human cell cultures to produce follicle stimulating hormone (FSH), which is used in in-vitro fertilization treatments. Ferring plans to expand production capabilities of the drug to meet market demand. BTG also develops and manufactures other medications using biological methods. The company hopes to create an ecosystem for biotech companies to thrive in Israel and become a hub for research, development, and manufacturing in the biotech industry.
Expand
Ferring invests $15m in Israeli unit Bio-Technology General
Ferring Pharmaceuticals is investing $15 million to expand biotech production capabilities at its Israeli subsidiary Bio-Technology General (BTG). The investment will support the development of new treatments in reproductive medicine and women’s health, as well as the manufacturing of the active pharmaceutical ingredient (API) for Ferrings latest fertility treatment, Rekovelle. The expansion will allow Ferring to maintain its scientific leadership in the fertility field and create innovative solutions for patients. BTG, founded in 1980, is the longest-standing bio-pharmaceutical company in Israel and employs around 300 people in its plant in Beer Tuvia Industrial Park.
Investment
https://www.ferring.com/en/media/press-releases/btg/
